methyl (E)-4-phenyl-2-butenoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl (E)-4-phenyl-2-butenoate
• 英文别名: methyl (E)-4-phenylbut-2-enoate；(E)-methyl 4-phenylbut-2-enoate
• 化学式: C₁₁H₁₂O₂
• 分子量: 176.215
• InChiKey: RQGQILSLSHKEMT-WEVVVXLNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl (E)-4-phenyl-2-butenoate 在 二异丁基氢化铝 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 17.25h， 生成 (E)-1-(4-phenylbut-2-en-1-yl)piperazine
  参考文献：
  名称：

  Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands

  摘要：

  In this letter, we describe a series of 4-substituted piperidine and piperazine compounds based on tetrahydroquinoline 1, a compound that shows balanced, low nanomolar binding affinity for the mu opioid receptor (MOR) and the delta opioid receptor (DOR). We have shown that by changing the length and flexibility profile of the side chain in this position, binding affinity is improved at both receptors by a significant degree. Furthermore, several of the compounds described herein display good efficacy at MOR, while simultaneously displaying DOR antagonism. The MOR agonist/DOR antagonist has shown promise in the reduction of negative side effects displayed by selective MOR agonists, namely the development of dependence and tolerance. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.021
• 作为产物：
  描述：

  2-氧代-4-苯基丁酸 在 氯化亚砜 、 copper diacetate 、 一水合肼 、 苯甲酸 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 3.0h， 生成 methyl (E)-4-phenyl-2-butenoate
  参考文献：
  名称：

  Highly effective one pot reaction from α-hydrazonoesters to give anilinoesters via α-diazoesters

  摘要：

  DOI：

  10.1016/j.tetlet.2024.154942

文献信息

• [EN] PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉ DE SULFAMATE DE PHÉNYLALKYLE ET COMPOSITION MYORELAXANTE LE CONTENANT
  申请人：BIO PHARM SOLUTIONS CO LTD

  公开号：WO2013187727A1

  公开（公告）日：2013-12-19

  The present invention relates to novel phenylalkyl sulfamate compounds, a method for preventing or treating a disease associated with muscle spasm. The present invention ensures the enhancement of muscle relaxation activity essential for alleviation of muscle spasm, such that it is promising for preventing or treating various diseases associated with muscle spasm.

  本发明涉及新型苯基烷基磺酰胺化合物，一种用于预防或治疗与肌肉痉挛相关疾病的方法。本发明确保增强肌肉松弛活性，这对于缓解肌肉痉挛至关重要，因此有望预防或治疗与肌肉痉挛相关的各种疾病。
• Pyrrolidine derivatives
  申请人：——

  公开号：US20020049243A1

  公开（公告）日：2002-04-25

  The present invention relates to pyrrolidine derivatives and dimeric forms and/or pharmaceutically acceptable esters, and/or salts thereof. The compounds are useful as inhibitors of metalloproteases, e.g. zinc proteases, particularly zinc hydrolases, and which are effective in treating disease states are associated with vasoconstriction of increasing occurrences.

  本发明涉及吡咯烷衍生物及其二聚体形式和/或药用可接受的酯和/或盐。这些化合物可用作金属蛋白酶抑制剂，例如锌蛋白酶，特别是锌水解酶，对治疗与血管收缩增加发生相关的疾病状态有效。
• Novel multi-dentate phosphines for Pd-catalyzed alkoxycarbonylation of alkynes promoted by H2O additive
  作者：Da Yang、Lei Liu、Dong-Liang Wang、Yong Lu、Xiao-Li Zhao、Ye Liu

  DOI：10.1016/j.jcat.2019.01.031

  日期：2019.3

  A series of novel multi (bi-/tri-/tetra-)-dentate phosphines with good robustness against water and oxygen were synthesized and fully characterized. It was found that the developed ionic tri-dentate phosphine (L2′) enabled Pd-catalyzed alkoxycarbonylation of alkynes most efficiently while H2O was used as an additive instead of acid. As for L2′, its unique steric configuration with two types of potential

  合成并充分表征了一系列新颖的多（双-/三-/四-）齿状膦，其对水和氧具有良好的耐受性。发现开发的离子型三齿膦（L2'）能够最有效地Pd催化炔烃的烷氧基羰基化，同时使用H 2 O代替酸作为添加剂。至于L2'，其独特的空间构型以及两种潜在的PP螯合模式（P⋯P距离分别为4.31Å和4.36Å）到Pd中心使得相应的Pd催化剂具有高活性和良好的炔烃羰基羰基化稳定性。的原位FT-IR分析也证实了钯-H活性物质的形成和稳定性大大用的存在促进L2'和H 2 O添加剂。此外，作为离子化膦，固定在[Bmim] NTf 2的RTIL中的基于L2'的PdCl 2（MeCN）2系统可以循环使用7次，而不会造成明显的活性损失或金属浸出。
• [EN] HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LA MODULATION DE NR2F6
  申请人：TES PHARMA S R L

  公开号：WO2021170658A1

  公开（公告）日：2021-09-02

  The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.

  本公开涉及能够调节NR2F6活性的化合物。本公开的化合物可用于预防及/或治疗与调节NR2F6活性相关疾病和障碍的方法。
• [EN] SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY<br/>[FR] COMPOSÉ DÉRIVÉ DE SULFAMATE DESTINÉ À ÊTRE UTILISÉ DANS LA PRÉVENTION OU LE TRAITEMENT DE L'ÉPILEPSIE
  申请人：BIO PHARM SOLUTIONS CO LTD

  公开号：WO2015088271A1

  公开（公告）日：2015-06-18

  The present invention relates to a pharmaceutical composition for treating or preventing epilepsy containing a sulfamate derivative compound and/or pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the present invention relates to a method for treatment or prevention epilepsy comprising administering a sulfamate derivative compound in a pharmaceutically effective amount to a subject in need of treatment or prevention of epilepsy.

  本发明涉及一种用于治疗或预防癫痫的药物组合物，其包含磺酰胺衍生物化合物和/或其药用可接受的盐作为活性成分。此外，本发明涉及一种治疗或预防癫痫的方法，包括向需要治疗或预防癫痫的受试者施用磺酰胺衍生物化合物的药用有效量。